An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

"We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on ...

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

Cdks are functional homologs across eukaryotes and are the engines that drive cell cycle events and the clocks that time them. Their function is counteracted by stoichiometric inhibitors; specifically ...

Palbociclib, a well-tolerated and selective CDK4/6 inhibitor ... were assessed in human liver cancer cell lines and human HCC samples by protein and gene expression analyses. Results Palbociclib ...

1Department of Obstetrics and Gynecology, Peking University Third Hospital, China 2Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China. 3Biobank, Peking ...

Melanoma brain metastasis is linked to dismal prognosis and low overall survival and is detected in up to 80% of patients at autopsy. Circulating tumor cells (CTC) are the smallest functional units of ...

Cyclic-dependent kinases (CDKs) are a family of serine/threonine kinases ... Various approaches targeting CDK2 have been shown to induce cell cycle arrest and tumor growth inhibition. The present ...